AIM ImmunoTech Trial of Ampligen With AstraZeneca's Imfinzi to Treat Pancreatic Cancers Doses Last Patient

MT Newswires Live06-18

AIM ImmunoTech (AIM) said Thursday that the last patient has received their first dose in the phase 2 DURIPANC clinical trial of Ampligen in combination with AstraZeneca's (AZN) anti-PD-L1 immune checkpoint inhibitor Imfinzi to treat metastatic pancreatic cancer.

The immuno-pharma company said it expects primary endpoint analysis to begin in December, with topline results expected in Q1 of 2027. The primary endpoint is clinical benefit rate, which is the proportion of patients achieving stable disease, partial response or complete response at 24 weeks following the initiation of combination therapy.

Analysis of the secondary endpoints is expected to begin in June 2027.

Shares of AIM ImmunoTech were up 4% pre-bell.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2644089856?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-18 21:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2644089856","market":"nz","top_or_hot":-1,"title":"AIM ImmunoTech Trial of Ampligen With AstraZeneca's Imfinzi to Treat Pancreatic Cancers Doses Last Patient","media":"MT Newswires Live","content":"<html><body><p> AIM ImmunoTech (AIM) said Thursday that the last patient has received their first dose in the phase 2 DURIPANC clinical trial of Ampligen in combination with AstraZeneca's (AZN) anti-PD-L1 immune checkpoint inhibitor Imfinzi to treat metastatic pancreatic cancer.</p><p>The immuno-pharma company said it expects primary endpoint analysis to begin in December, with topline results expected in Q1 of 2027. The primary endpoint is clinical benefit rate, which is the proportion of patients achieving stable disease, partial response or complete response at 24 weeks following the initiation of combination therapy.</p><p>Analysis of the secondary endpoints is expected to begin in June 2027.</p><p>Shares of AIM ImmunoTech were up 4% pre-bell.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AIM ImmunoTech Trial of Ampligen With AstraZeneca's Imfinzi to Treat Pancreatic Cancers Doses Last Patient</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAIM ImmunoTech Trial of Ampligen With AstraZeneca's Imfinzi to Treat Pancreatic Cancers Doses Last Patient\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-18 21:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> AIM ImmunoTech (AIM) said Thursday that the last patient has received their first dose in the phase 2 DURIPANC clinical trial of Ampligen in combination with AstraZeneca's (AZN) anti-PD-L1 immune checkpoint inhibitor Imfinzi to treat metastatic pancreatic cancer.</p><p>The immuno-pharma company said it expects primary endpoint analysis to begin in December, with topline results expected in Q1 of 2027. The primary endpoint is clinical benefit rate, which is the proportion of patients achieving stable disease, partial response or complete response at 24 weeks following the initiation of combination therapy.</p><p>Analysis of the secondary endpoints is expected to begin in June 2027.</p><p>Shares of AIM ImmunoTech were up 4% pre-bell.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2237443978.SGD","symbol_name":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2644089856","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2644089856","pubTimestamp":1781789085,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"AIM ImmunoTech  said Thursday that the last patient has received their first dose in the phase 2 DURIPANC clinical trial of Ampligen in combination with AstraZeneca's  anti-PD-L1 immune checkpoint inhibitor Imfinzi to treat metastatic pancreatic cancer.The immuno-pharma company said it expects primary endpoint analysis to begin in December, with topline results expected in Q1 of 2027. The primary endpoint is clinical benefit rate, which is the proportion of patients achieving stable disease, partial response or complete response at 24 weeks following the initiation of combination therapy.Analysis of the secondary endpoints is expected to begin in June 2027.Shares of AIM ImmunoTech were up 4% pre-bell.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","BK4585":"ETF&股票定投概念","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","BK4139":"生物科技","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","AZN":"阿斯利康","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","BK4557":"大麻股","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","AIM":"AIM ImmunoTech Inc.","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4568":"美国抗疫概念","BK4588":"碎股","LU1829250122.USD":"高盛欧洲核心股票组合Acc","AZNH":"ASTRAZENECA PLC ADRhedged","LU0058720904.USD":"联博国际健康护理基金A","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","BK4007":"制药","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","BK7064":"综合支持服务","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","AIM.AU":"Ai-Media Technologies Ltd"},"translate_title":"AIM免疫技术试验Ampligen与阿斯利康的Imfinzi治疗胰腺癌剂量最后一名患者","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AIM.AU":1,"AZN":1,"AIM":1.5,"AZNH":0.6},"content_text":"AIM ImmunoTech (AIM) said Thursday that the last patient has received their first dose in the phase 2 DURIPANC clinical trial of Ampligen in combination with AstraZeneca's (AZN) anti-PD-L1 immune checkpoint inhibitor Imfinzi to treat metastatic pancreatic cancer.The immuno-pharma company said it expects primary endpoint analysis to begin in December, with topline results expected in Q1 of 2027. The primary endpoint is clinical benefit rate, which is the proportion of patients achieving stable disease, partial response or complete response at 24 weeks following the initiation of combination therapy.Analysis of the secondary endpoints is expected to begin in June 2027.Shares of AIM ImmunoTech were up 4% pre-bell.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2644089856","isCrawlerRequest":true}